{"filings":[{"id":513159,"accession_number":"0001213900-26-058795","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-19T14:32:30+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company","event_type":"m_and_a","confidence":"high","bullets":["Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.","Concurrent $290M private placement led by Fairmount; funds operations through 2028.","Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.","Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.","Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":"2026-05-19","daily_digest_url":"/daily/2026-05-19","daily_digest_rank":1},{"id":507958,"accession_number":"0001062993-26-002787","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-19T10:03:08+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"InMed amends Armistice option exercise price from $16.60 to $0.80 per share","event_type":"other_material","confidence":"high","bullets":["Up to 278,761 common shares subject to options; exercise price reduced to $0.80 from $16.60.","Options originally issued October 26, 2023; amendment entered May 18, 2026.","Dramatic price reduction may increase dilution risk for existing shareholders if exercised.","Press release issued May 19, 2026 confirms amendment; no assurance options will be exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95041,"accession_number":"0001062993-26-002371","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.","R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.","Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.","INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.","Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95040,"accession_number":"0001213900-26-048064","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80","event_type":"other_material","confidence":"high","bullets":["Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.","Wainwright options exercise price reduced to $0.80 from $82.50, $20.75, and $3.2013 for 153,236 shares.","Amendments signed April 21 and April 24, 2026; announced April 27.","Lower exercise price could lead to exercise and dilution of existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95039,"accession_number":"0001213900-26-039943","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed files prospectus supplement for ATM offering of common shares under existing Sales Agreement","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement dated April 3, 2026 for at-the-market equity offering.","ATM facility is under Sales Agreement with H.C. Wainwright & Co., originally dated April 7, 2022, amended June 27, 2024.","Shelf registration statement on Form S-3 (File No. 333-294503) declared effective March 30, 2026.","No specific number of shares or dollar amount disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107829,"accession_number":"0001062993-26-001697","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"InMed receives Nasdaq notice of bid price deficiency; 180 days to cure","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).","Must achieve $1.00 or more for 10 consecutive business days within 180 calendar days to regain compliance.","If not cured, may qualify for additional 180-day period, subject to other listing standards and possible reverse split.","No immediate effect on listing; shares continue trading on Nasdaq under symbol INM.","Company monitoring share price and exploring options, including reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107828,"accession_number":"0001062993-26-001567","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed reports positive INM-901 data in human brain organoid neuroinflammation models","event_type":"other_material","confidence":"high","bullets":["INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.","Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.","Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.","Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.","Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107827,"accession_number":"0001062993-26-001347","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089","event_type":"other_material","confidence":"high","bullets":["Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.","Targeting pre-IND meeting with FDA for INM-901 in Q3 2026 and for INM-089 in Q4 2026.","INM-901 aims for IND submission and Phase 1 clinical trial initiation in 2027.","INM-089 (dry AMD) completed dose-ranging studies; drug substance process in place for IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107826,"accession_number":"0001213900-26-024752","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline","event_type":"other_material","confidence":"high","bullets":["Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.","Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.","Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.","Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107825,"accession_number":"0001062993-26-000819","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed Q2 FY2026 net loss $2.03M; cash drops to $7.0M; warns of material impact from pending US legislation on BayMedica","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.","Cash and equivalents $7.0M at Dec 31, 2025 vs $11.1M at June 30, 2025; expects runway into Q4 calendar 2026.","BayMedica revenues $0.8M, down 26% YoY, due to pending US legislation H.R. 5371 that may prohibit certain cannabinoid sales after Nov 12, 2026.","INM-901 Alzheimer's candidate advanced: oral formulation showed robust bioavailability in large animal PK study; no adverse neural effects.","R&D expenses fell to $0.6M from $0.9M; expects substantial increase in H2 FY2026 for IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1940309.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124226,"accession_number":"0001062993-25-017390","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"InMed shareholders re-elect all five directors, approve auditor and share issuance at AGM","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 81.9% to 82.1% support.","Appointment of CBIZ CPAs P.C. as auditor for 2026 approved (78.8% for).","Shareholders approved potential issuance of >=20% of shares under SEPA with YA II PN (65.9% for).","Turnout was 993,491 shares (35.43% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124225,"accession_number":"0001213900-25-121497","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"New US law to materially hurt InMed's BayMedica cannabinoid business; core pharma programs unaffected","event_type":"regulatory","confidence":"high","bullets":["H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.","BayMedica is evaluating alternative supply chain options to maintain regulatory compliance.","InMed's pharmaceutical programs (INM-901 for Alzheimer's, INM-089 for AMD) are not affected by the legislation.","Company warns of material negative impact on BayMedica's contribution to consolidated financial results.","Act may be amended before Nov 12, 2026, but current form already enacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124224,"accession_number":"0001213900-25-112644","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model","event_type":"other_material","confidence":"high","bullets":["Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.","Neurological assessments found no adverse effects on attitude, behavior, or motor function.","Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.","Data support design of first-in-human Phase 1 clinical trial for INM-901."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124223,"accession_number":"0001213900-25-099529","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InMed appoints John Bathery to board; director Baldasare to depart at AGM","event_type":"leadership","confidence":"high","bullets":["John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.","Bathery has 30+ years pharma experience, currently Head of Global BD at Takeda, led deals exceeding $60B.","Bryan Baldasare will not stand for re-election at 2025 AGM due to increasing professional obligations; no disagreements.","Bathery's expertise expected to support INM-901 (Alzheimer's) and INM-089 (AMD) programs toward clinical readiness and partnerships.","Bathery receives standard non-employee director compensation: $50,000 annual retainer, potential committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124222,"accession_number":"0001213900-25-098229","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"InMed announces Dec 17, 2025 annual meeting; record date Oct 22, 2025","event_type":"other","confidence":"high","bullets":["Annual general and special meeting set for December 17, 2025.","Record date for notice and voting is October 22, 2025.","Meeting will consider matters typical for annual meetings; no specific proposals detailed.","Company filed notice via SEDAR; proxy materials to be sent using notice and access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124221,"accession_number":"0001213900-25-098205","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InMed appoints Neil Klompas to board, effective October 9, 2025","event_type":"leadership","confidence":"high","bullets":["Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.","Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.","Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.","He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.","No related party transactions or family relationships with any director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140895,"accession_number":"0001213900-25-090715","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.","Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.","BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.","INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.","INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140894,"accession_number":"0001213900-25-090695","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"InMed sets Dec 17, 2025 annual meeting; record date Oct 22, 2025","event_type":"other","confidence":"high","bullets":["Annual General Meeting on December 17, 2025.","Record date for notice and voting: October 22, 2025.","Securities entitled to vote: Common Shares (ISIN CA4576377002).","Notice and Access method will be used for both beneficial and registered holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140893,"accession_number":"0001213900-25-085213","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to participate in H.C. Wainwright 27th Annual Global Investment Conference","event_type":"other","confidence":"high","bullets":["Conference takes place September 8-10, 2025 in New York.","Management will conduct one-on-one investor meetings and a corporate presentation is available online.","COO Michael Woudenberg will highlight pipeline updates including INM-901 Alzheimer's program data from AAIC 2025.","No new financial or operational results disclosed; presentation is for investor outreach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140892,"accession_number":"0001213900-25-068190","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity","event_type":"other_material","confidence":"high","bullets":["Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.","Long-term study in 5xFAD mouse model with advanced disease; treatment duration longer than previous studies.","INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in dose-dependent manner.","Immunohistochemistry showed dose-dependent reduction in amyloid-beta immunoreactivity and partial restoration of MAP2.","Behavioral improvements: cognitive function, anxiety-related behavior, sensory responsiveness restored or approaching normal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158651,"accession_number":"0001213900-25-059673","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"InMed Pharma raises $5M in private placement of pre-funded warrants and options","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from 1,952,363 pre-funded warrants ($0.0001 exercise) and 1,952,363 preferred investment options at $2.436/share.","Amended 199,115 existing options (Oct 2023) from $16.60 to $2.436 per share for $0.125 each.","Proceeds to fund pipeline development, BayMedica commercial sales, and working capital.","H.C. Wainwright acted as placement agent; received 126,904 agent options at $3.2013/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158650,"accession_number":"0001213900-25-057139","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study","event_type":"other_material","confidence":"high","bullets":["INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.","INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.","Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.","Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158649,"accession_number":"0001213900-25-054315","cik":1728328,"company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","4.01","5.07","9.01"],"status":"ready","headline":"InMed special meeting lacks quorum for share issuance vote; appoints new auditor CBIZ","event_type":"other_material","confidence":"high","bullets":["Special meeting on June 13, 2025 lacked quorum; ~60% of voted shares favored share issuance proposal but no vote held. Board evaluating next steps.","Marcum resigned as auditor after acquisition by CBIZ; Board appointed CBIZ as independent auditor for FY2025. No disagreements; prior material weakness remediated.","Company amended SEPA with Yorkville to allow suspension of registration statement during black-out periods, subject to restrictions similar to insider trading policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}